Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genscript Biotech Corporation

https://www.genscript.com/

Latest From Genscript Biotech Corporation

Stock Watch: Beware The Halo Effect Of Biopharma Leaders

Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.

Stock Watch Leadership

US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?

Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.

Sales & Earnings OTC Drugs

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Financing Growth

IPO Update: Mid-Year Average Return Deceptively Positive In Down Market

The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities. 

Financing Growth
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • CustomArray
    • Legend Biotech USA Inc.
    • Legend Biotech Ireland Limited
    • Nanjing GenScript Co Ltd
    • Nanjing Legend Biotechnology Co., Ltd.
    • GenScript ProBio
UsernamePublicRestriction

Register